BAJAJ BROKING

Notification close image
No new Notification messages
card image
Accretion Pharmaceuticals IPO is Open!
Apply for the Accretion Pharmaceuticals IPO through UPI in just minutes.
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Accretion Pharmaceuticals IPO: Things Smart Investors Need to Know

Accretion Pharmaceuticals Limited, incorporated in 2012, is a fast-growing pharmaceutical company engaged in the manufacturing and marketing of a wide range of healthcare products. Its diverse portfolio includes tablets, capsules, oral liquids, oral powders (like sachets and dry syrups), and external preparations such as ointments, creams, gels, lotions, medicated shampoos, mouthwash, and dusting powders. The company not only serves direct markets but also offers contract and loan licence manufacturing for various third-party marketers. With operations primarily on a principal-to-principal basis, Accretion caters to a wide range of corporate clients, reflecting its strong presence in the pharmaceutical supply chain.

Headquartered in Sanand, Ahmedabad, Gujarat, Accretion Pharmaceuticals boasts ISO 9001:2015, ISO 14001:2015, and ISO 22000:2018 certifications, highlighting its adherence to quality, safety, and environmental standards. Backed by a skilled leadership team and professional management, the company has extended its reach to over 20 countries, including regions in Africa, Southeast Asia, and the Middle East, showcasing its global ambitions and operational strength.

For more details, visit the Accretion Pharmaceuticals IPO page.

Accretion Pharmaceuticals IPO Details and Objectives

Details

Information

IPO Date

May 14, 2025 to May 16, 2025

Issue Size

29,46,000 shares

(aggregating up to ₹29.75 Cr)

Price Band

₹96 to ₹101 per share

Lot Size

1200 shares

Listing At

NSE SME

Market Maker

Gretex Share Broking Private Limited

Purpose of the IPO

  • Purchase of machinery and equipment

  • Funding Working capital requirements

  • General Corporate Purpose

Timeline of Accretion Pharmaceuticals IPO

Event

Date

IPO Open Date

Wed, May 14, 2025

IPO Close Date

Fri, May 16, 2025

Tentative Allotment

Mon, May 19, 2025

Initiation of Refunds

Tue, May 20, 2025

Credit of Shares to Demat

Tue, May 20, 2025

Tentative Listing Date

Wed, May 21, 2025

Cut-off time for UPI mandate confirmation

5 PM on May 16, 2025

Pricing & Lot Size of Accretion Pharmaceuticals IPO

Price Band for the IPO

  • ₹96 to ₹101 per share

Minimum Lot Size and Application Details

Application

Lots

Shares

Amount

Retail (Min)

1

1200

₹1,21,200

Retail (Max)

1

1200

₹1,21,200

HNI (Min)

2

2,400

₹2,42,400

How to Apply for the Accretion Pharmaceuticals IPO?

Online Application Process

  • Log in to Your Trading Account
    Access your trading account through your broker’s platform.

  • Navigate to the IPO Section
    Go to the IPO section to view active IPO listings.

  • Select Accretion Pharmaceuticals IPO
    Find "Accretion Pharmaceuticals IPO" and click on the ‘Apply’ button.

  • Enter Application Details
    Specify the number of lots (minimum lot size: 1200 shares) and the bid price within the range of ₹96 to ₹101 per share.

  • Provide Your UPI ID
    Enter your UPI ID for payment authorization. Ensure that sufficient funds are available in your linked account.

  • Review and Submit
    Verify all the details entered before submitting the application. Approve the UPI mandate before 5 PM on May 16, 2025, to complete your application process.

Financial Health and Performance

Key Financial Metrics

  • Total Assets: Grew from ₹17.74 crore in FY22 to ₹39.99 crore as of December 2024.

  • Revenue: Reached ₹35.75 crore in FY24.

  • Profit After Tax (PAT): Stood at ₹5.24 crore for December 2024.

  • Net Worth: Increased from ₹3.08 crore in FY22 to ₹13.58 crore as of December 2024.

  • Reserves and Surplus: Recorded at ₹5.41 crore (Dec 2024), growing steadily over the years.

  • Total Borrowings: Stood at ₹13.79 crore in December 2024.

Recent Performance and Growth Prospects

  • The company has shown strong financial growth, with a notable increase in total assets over the last few years.

  • Revenue generation has been consistent, indicating healthy market demand and effective business operations.

  • Profitability has improved significantly, reflecting efficient cost management and operational performance.

  • The company’s net worth has seen a substantial rise, suggesting strengthened financial stability and investor confidence.

  • Reserves and surplus have been steadily growing, supporting the company’s long-term financial health and future expansion plans.

  • While the company does carry borrowings, its overall growth trajectory highlights a balanced approach to leveraging and investment.

Investment Risks and Opportunities

Potential Risks of Investing in the IPO

  • High dependency on contract manufacturing: A large portion of Accretion Pharmaceuticals’ business comes from third-party contracts and loan licence manufacturing. Any loss or non-renewal of such contracts could impact revenue streams.

  • SME listing limitations: Since the IPO is being launched on the NSE SME platform, liquidity may be lower than mainboard listings, potentially resulting in limited exit opportunities for investors.

Opportunities and Growth Potential

  • Global market expansion: With its presence in over 20 countries and growing international demand, Accretion Pharmaceuticals is well-positioned to strengthen its global footprint and revenue base.

  • Robust infrastructure and compliance: The company’s ISO certifications and modern manufacturing facility in Gujarat reflect strong operational capabilities, helping it attract new clients and scale operations.

Key Performance Indicator (KPI)

KPI

Values

ROE

72.47%

ROCE

36.73%

Debt/Equity

2.52

RoNW

72.47%

PAT Margin

11.51

Price to Book Value

7.55

Accretion Pharmaceuticals IPO Registrar & Lead Managers

Registrar

Lead Manager(s)

Kfin Technologies Limited

Jawa Capital Services Private Limited 

Company Address of Accretion Pharmaceuticals Ltd

Accretion Pharmaceuticals Limited

29 Xcelon Ind Park 1,

B/h, Intas Pharmaceuticals, Vasna Chacharvad

Sanand,

Phone: +91-97148 82929

Email: compliance@accretionpharma.com

Website: https://accretionpharma.com/

Conclusion

Accretion Pharmaceuticals Limited has developed a wide-ranging healthcare portfolio and operates across domestic and international markets. Its business model incorporates both direct marketing and third-party manufacturing arrangements, supported by certified processes and operational infrastructure. The company’s financial metrics indicate an upward trend in key areas, including revenue, profit, and net worth.

With its proposed IPO on the NSE SME platform, the company intends to raise capital for machinery purchases, working capital, and general corporate needs. Investors may consider the IPO timeline, lot size, and associated risks before proceeding through the application process.

Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Accretion Pharmaceuticals IPO.

Share this article: 

Frequently Asked Questions

No result found

search icon

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4300+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|